Hematologic Oncology | Specialty

The TRANSCEND-NHL-001 Trial

December 23rd 2019

CAR T Associated Cytokine Release Syndrome

December 23rd 2019

Real-World Data and CAR T Therapy

December 23rd 2019

CAR-T Therapy Treatment Variables

December 23rd 2019

High-Risk Lymphoma: The ZUMA-1 and SCHOLAR-1 Trials

December 23rd 2019

Adult ALL and Data from ZUMA-3

December 23rd 2019

CAR T-Cell Therapy: Relapsed/Refractory ALL

December 23rd 2019

Treating Common Toxicities From CAR T Therapy

December 23rd 2019

A Conversation on MRD in ALL

December 23rd 2019

CAR T-Cell Therapy in Pediatric ALL

December 23rd 2019

Understanding of MRD and CAR T-Cell Therapy in ALL Continues to Evolve

December 23rd 2019

Minimal residual disease has become an important investigational prognostic marker and risk stratification tool in acute lymphoblastic leukemia.

MSK Researchers Making Strides in Hematologic Malignancies

December 21st 2019

Faculty from Memorial Sloan Kettering Cancer Center shed light on some of the intriguing research in hematologic cancer being conducted at their institution.

FDA Approval Sought for Tazemetostat in Follicular Lymphoma

December 19th 2019

A new drug application has been submitted to the FDA for tazemetostat as a treatment for patients with relapsed/refractory follicular lymphoma, with or without EZH2 activating mutations, who have received ≥2 prior lines of systemic therapy.

Dr. Noy on the Rationale to Evaluate Devimistat in Burkitt Lymphoma

December 19th 2019

Ariela Noy, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the rationale to evaluate devimistat (CPI-613) in patients with either Burkitt lymphoma/leukemia or high-grade B-cell lymphoma.

Brentuximab Vedotin Demonstrates Durable Long-Term PFS Benefit in Hodgkin Lymphoma

December 18th 2019

The addition of brentuximab vedotin to standard 3-drug chemotherapy for patients with newly diagnosed, advanced-stage classical Hodgkin lymphoma continued to outperform a 4-drug chemotherapy standard.

FDA Grants Ivosidenib Breakthrough Status for Relapsed/Refractory IDH1+ MDS

December 18th 2019

The FDA has granted a breakthrough therapy designation to ivosidenib for the treatment of adult patients with relapsed/refractory myelodysplastic syndromes who harbor IDH1 mutations.

ADC Targeting CD123 Active in R/R AML and BPDCN

December 18th 2019

IMGN632, an investigational anti-CD123 antibody-drug conjugate, demonstrated preliminary activity in patients with relapsed/refractory acute myelogenous leukemia or blastic plasmacytoid dendritic cell neoplasm.

Zanubrutinib Misses Response Endpoint in Waldenstrom Macroglobulinemia, But Trends Toward Clinical Benefit

December 17th 2019

Zanubrutinib did not show a statistically significant improvement in complete response and very good partial response rates compared with ibrutinib in patients with Waldenström macroglobulinemia, missing the primary endpoint of the phase III ASPEN trial.

Resistance-Targeting BTK Inhibitor ARQ 531 Active Across B-Cell Malignancies

December 17th 2019

The investigational Bruton tyrosine kinase inhibitor ARQ 531 demonstrated safety and clinical activity across a range of B-cell malignancies.

Luspatercept Reduces Transfusion Burden in Transfusion-Dependent Patients With Beta-Thalassemia

December 11th 2019

A majority of adult patients with β-thalassemia who require regular red blood cell transfusions experienced clinically meaningful and durable transfusion burden reduction associated with luspatercept (Reblozyl).